FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
FDA added bemotrizinol to the list of permitted sunscreen active ingredients, marking the first new active ingredient added to the over-the-counter sunscreen monograph since the late 1990s.
